Although the U.K.'s life sciences sector anticipates Brexit will hit academia worse than industry, a research brain drain could have repercussions for the whole ecosystem.
A UPenn team has adapted CAR T cell technology to target autoimmune cells, and believes the strategy may work as well in autoimmunity as it does in cancer, with fewer liabilities.
EMERGING COMPANY PROFILE
PhoreMost's Protein-interference platform can identify targets and reveal how to drug them at the same time.
TRANSLATION IN BRIEF
A host protein that all flaviviruses use to reproduce could lead to a general-purpose treatment for Zika, dengue and others in the class.
An OHSU group has made a gene therapy platform that uses drug selection in vivo to give a proliferation advantage to cells that receive and integrate the gene.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.